AVANIR raises funds to develop and commercialize Zenvia for PBA AVANIR Pharmaceuticals, Inc. today announced it acquired raised gross proceeds of approximately $10.6 million via the sale of 4 approximately.5 million shares of common stock at a weighted average price of $2.34 per talk about. The Company currently expects to curtail extra sales beneath the facility in the near future and can evaluate its capital wants and additional funding alternatives. 333-158665).In addition, appropriate antitachycardia pacing was significantly less regular in the high-rate and delayed-therapy organizations than in the conventional-therapy group, a finding that suggests that many episodes of nonsustained ventricular tachycardia that would have terminated spontaneously had been treated prematurely in the conventional-therapy group. In retrospect, such therapy could be considered unnecessary. The significant reduction in appropriate and inappropriate antitachycardia pacing in the high-rate and delayed-therapy groups may have contributed to the observed mortality reduction of 44 to 55 percent observed in this study, and the findings raise questions about the need for and safety of empirical antitachycardia pacing.